We are live on ! Find out more
HALO icon

Halozyme

607 hedge funds and large institutions have $8.85B invested in Halozyme in 2025 Q3 according to their latest regulatory filings, with 113 funds opening new positions, 189 increasing their positions, 239 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

122% more first-time investments, than exits

New positions opened: 113 | Existing positions closed: 51

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

52% more call options, than puts

Call options by funds: $52.5M | Put options by funds: $34.7M

38% more capital inflows, than outflows

Capital inflows: $1.16B | Capital outflows: $842M

10% more funds holding

Funds holding: 553 → 607 (+54)

8.79% more ownership

Funds ownership: 94.38% → 103.17% (+8.8%)

21% less repeat investments, than reductions

Existing positions increased: 189 | Existing positions reduced: 239

Holders
607
Holders Change
+54
Holders Change %
+9.76%
% of All Funds
7.92%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.07%
New
113
Increased
189
Reduced
239
Closed
51
Calls
$52.5M
Puts
$34.7M
Net Calls
+$17.9M
Net Calls Change
+$12.8M

HALO Hedge Fund Activity: Q3 2025 in Review

607 of the 7,663 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q3 2025, worth a combined $8.85B — up 46% from $6.05B a quarter earlier.

Buyers outnumbered sellers: 113 funds opened new HALO positions and 51 closed out — a net gain of 62 holders — while 189 added to existing stakes and 239 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $108M. The largest seller was State Street, cutting an estimated $60.8M.

  • 607 institutional investors held Halozyme (HALO) as of Q3 2025, up from 553 in Q2 2025.
  • Funds reported $8.85B of Halozyme stock for Q3 2025, up 46% quarter-over-quarter.
  • 113 funds opened new Halozyme positions in Q3 2025 and 51 closed out, a net change of +62 holders.
  • The largest Halozyme buyer in Q3 2025 was D.E. Shaw & Co, an estimated $108M added.
  • The largest Halozyme seller in Q3 2025 was State Street, an estimated $60.8M sold.

Based on aggregated 13F filings for Q3 2025.